Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Rudwaleit M, Brown M, Van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, De Peyrecave N, Vaux T, White K, et al. (2023)
Annals of the Rheumatic Diseases 82(Suppl. 1): 614-615.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Rudwaleit, MartinUniBi;
Brown, M.;
Van Gaalen, F. A.;
Haroon, N.;
Gensler, L. S.;
Fleurinck, C.;
Marten, A.;
Massow, U.;
De Peyrecave, N.;
Vaux, T.;
White, K.;
Deodhar, A.
Alle
Alle
Einrichtung
Stichworte
Spondyloarthritis;
Safety;
Uveitis
Erscheinungsjahr
2023
Serien- oder Zeitschriftentitel
Annals of the Rheumatic Diseases
Band
82
Ausgabe
Suppl. 1
Seite(n)
614-615
Konferenz
European Congress of Rheumatology (EULAR)
Konferenzort
Milan, ITALY
Konferenzdatum
2023-05-31 – 2023-06-03
ISSN
0003-4967
eISSN
1468-2060
Page URI
https://pub.uni-bielefeld.de/record/2987167
Zitieren
Rudwaleit M, Brown M, Van Gaalen FA, et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases. 2023;82(Suppl. 1):614-615.
Rudwaleit, M., Brown, M., Van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., et al. (2023). Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases, 82(Suppl. 1), 614-615. https://doi.org/10.1136/annrheumdis-2023-eular.1702
Rudwaleit, Martin, Brown, M., Van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., et al. 2023. “Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials”, Annals of the Rheumatic Diseases, 82 (Suppl. 1): 614-615.
Rudwaleit, M., Brown, M., Van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., Massow, U., De Peyrecave, N., Vaux, T., et al. (2023). Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases 82, 614-615.
Rudwaleit, M., et al., 2023. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases, 82(Suppl. 1), p 614-615.
M. Rudwaleit, et al., “Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials”, Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 614-615.
Rudwaleit, M., Brown, M., Van Gaalen, F.A., Haroon, N., Gensler, L.S., Fleurinck, C., Marten, A., Massow, U., De Peyrecave, N., Vaux, T., White, K., Deodhar, A., Van der Horst-Bruinsma, I.: Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases. 82, 614-615 (2023).
Rudwaleit, Martin, Brown, M., Van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., Massow, U., De Peyrecave, N., Vaux, T., White, K., Deodhar, A., and Van der Horst-Bruinsma, I. “Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials”. Annals of the Rheumatic Diseases 82.Suppl. 1 (2023): 614-615.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar